Gentian Diagnostics AS (OSL:GENT) ROIC %: -63.47% (As of Mar. 2026)


OSL:GENT Gentian Diagnostics AS OSL:GENT
72 GF Score
Price kr37.00
GF Value kr61.81
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Gentian Diagnostics AS ROIC %?

Gentian Diagnostics AS OSL:GENT -4.88% 72 ROIC % is -63.47% as of Mar. 2026. GuruFocus rates OSL:GENT with a GF Score™ of 72/100 and a GF Value™ of kr61.81 (Possible Value Trap). The stock has 1 warning sign investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Gentian Diagnostics AS's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -63.47%.

As of today (2026-07-04), Gentian Diagnostics AS's WACC % is 4.89%. Gentian Diagnostics AS's ROIC % is -11.28% (calculated using TTM income statement data). Gentian Diagnostics AS earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Gentian Diagnostics AS  (OSL:GENT) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Gentian Diagnostics AS's WACC % is 4.89%. Gentian Diagnostics AS's ROIC % is -11.28% (calculated using TTM income statement data). Gentian Diagnostics AS earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Gentian Diagnostics AS ROIC % Related Terms


Gentian Diagnostics AS ROIC % Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS ROIC % Chart

Gentian Diagnostics AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.18 -25.11 -14.03 14.47 9.53

Gentian Diagnostics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.66 -1.82 13.14 8.97 -63.47

OSL:GENT vs ABT, SYK, MDT: ROIC % Comparison

For the Medical Devices subindustry, Gentian Diagnostics AS's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS ROIC % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's ROIC % distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's ROIC % falls into.


OSL:GENT
72GF Score
Gentian Diagnostics AS OSL:GENT
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gentian Diagnostics AS ROIC % Calculation

Gentian Diagnostics AS's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=25.451 * ( 1 - 48.35% )/( (132.19 + 143.736)/ 2 )
=13.1454415/137.963
=9.53 %

where

Gentian Diagnostics AS's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-110.128 * ( 1 - 26.58% )/( (143.736 + 111.038)/ 2 )
=-80.8559776/127.387
=-63.47 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -63.47% mean?
Gentian Diagnostics AS (OSL:GENT) has a ROIC % of -63.47% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's ROIC % too high?
Gentian Diagnostics AS's current ROIC % is -63.47%. Overall, Gentian Diagnostics AS has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's ROIC % compare to ABT and SYK?
Gentian Diagnostics AS's ROIC % of -63.47% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROIC % is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Medical Devices & Instruments company?
The median ROIC % among Medical Devices & Instruments companies is 1.26, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median ROIC % is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current ROIC % is -63.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Possible Value Trap. The stock's GF Value™ is kr61.81, compared to a current price of kr37.00 — trading 40.1% below its estimated fair value. The current ROIC % is -63.47%. Gentian Diagnostics AS's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current ROIC % is -63.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr37.00 is trading 40.1% below its estimated GF Value™ of kr61.81. GuruFocus considers Gentian Diagnostics AS to be Possible Value Trap.

Key valuation signals for OSL:GENT:

  • ROIC %: -63.47%
  • GF Value™: kr61.81 vs. price of kr37.00 (40.1% below fair value)
  • GF Score™: 72/100 with 1 warning sign

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:Sweden6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
72GF Score

Get the complete analysis for OSL:GENT

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr37.00
Price
kr61.81
GF Value